Compare NXST & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXST | IMVT |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.8B |
| IPO Year | 2002 | 2019 |
| Metric | NXST | IMVT |
|---|---|---|
| Price | $187.57 | $33.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $263.75 | $33.00 |
| AVG Volume (30 Days) | 278.7K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.09 | N/A |
| Revenue | ★ $4,949,000,000.00 | N/A |
| Revenue This Year | $11.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $164.00 | $13.79 |
| 52 Week High | $254.30 | $36.29 |
| Indicator | NXST | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 64.98 |
| Support Level | $182.45 | $22.84 |
| Resistance Level | $210.51 | N/A |
| Average True Range (ATR) | 8.22 | 1.92 |
| MACD | -0.80 | 0.61 |
| Stochastic Oscillator | 13.44 | 76.17 |
Nexstar is the largest television station owner-operator in the United States with over 200 stations in 116 markets, reaching 220 million people. Of its 200 stations, 155 are affiliated with the four national broadcast networks: CBS, Fox, NBC, and ABC. Pending approval, Nexstar's merger with Tegna would bring Nexstar's station total to 259 in 133 markets, reaching 80% of the US population. Nexstar also owns NewsNation (formerly WGN), a cable news network, 75% of the fifth national broadcaster, the CW, and a 31% stake in Food Network and Cooking Channel.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.